Ready to expand, GenScript raises $224M for CDMO focused on antibodies, cell and gene therapies
China’s GenScript has brought in new investors to back its biologics-focused subsidiary — to the tune of $224 million.
GenScript, which is listed in Hong Kong, disclosed the Series C for GenScript ProBio in a filing. The new funds will help “build up manufacturing capacity, further research and development capabilities and opportunistically acquire assets” to develop ProBio’s contract development and manufacturing business, the mother company wrote.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters